<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00815386</url>
  </required_header>
  <id_info>
    <org_study_id>08-037P</org_study_id>
    <nct_id>NCT00815386</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of the PTMA Device to Reduce Mitral Valve Regurgitation in Patients With Heart Failure</brief_title>
  <acronym>PTOLEMY2Canada</acronym>
  <official_title>Safety and Efficacy of Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viacor</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medifacts International Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Viacor</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Improvement in heart failure with moderate to severe mitral regurgitation using a
      percutaneously delivered implantable device residing in the coronary sinus
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Device under Test: The ViacorÂ® Percutaneous Transvenous Mitral Annuloplasty (PTMA) system
      comprises a sterile implantable cardiac device and associated custom accessories to assist
      implantation. The PTMA system is intended to treat functional mitral regurgitation (MR) in a
      heart failure patient by a less invasive method than surgical annuloplasty with greater
      relief of symptoms than medical management alone.

      Study Objective: Functional mitral regurgitation is associated with an adverse prognosis in
      the heart failure patient. The objective of this study is to evaluate whether PTMA is
      effective in reducing mitral regurgitation in heart failure patients and whether this
      reduction is associated with a moderation in the adverse progression of heart failure
      symptoms.

      Hypothesis under Test: Reduction of the severity of functional mitral regurgitation from
      baseline, as defined by a composite improvement of quantitative echocardiographic metrics,
      can be achieved safely with the PTMA device and will be associated with a measurable
      moderation of adverse progression of heart failure symptoms and a moderation of the
      deterioration of exercise capacity.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Company ended operations in January 2011
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of mitral regurgitation</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from major adverse cardiac events (death, MI, emergent cardiac surgery, and stroke).</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of 6 minute walk distance</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Quality of Life Score</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of mitral regurgitation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from procedure-related or device-related major adverse events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Mitral Regurgitation</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>PTMA implanted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled patients receiving a PTMA implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous transvenous mitral annuloplasty</intervention_name>
    <description>Catheterization procedure with anesthesia requiring subclavicular puncture, catheterization of the right atrium and coronary sinus vein, placement and optimization of the PTMA device with access hub remaining subcutaneous at the clavicle.</description>
    <arm_group_label>PTMA implanted</arm_group_label>
    <other_name>mitral annuloplasty</other_name>
    <other_name>sinoplasty</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has moderate functional MR: regurgitant orifice area &gt;/= 0.20cm2 or
             regurgitant volume &gt;/= 30 mL/beat or regurgitant fraction &gt;/= 30%

          -  Symptomatic heart failure NYHA Class II to IV

          -  LV dysfunction (25% &lt; LVEF &lt; 50% by echocardiography) OR dilated mitral annulus &gt; 30mm

        Exclusion Criteria:

          -  MR of organic origin

          -  Severe mitral leaflet tethering

          -  History of MI or PCI within 60 days of study procedure

          -  Inability to walk a minimum of 100 meters in 6 minutes

          -  Significant left main stenosis or proximal circumflex stent

          -  Indication of non-patent CSO or discontinuous CS-GCV-AIV

          -  Bi-ventricular with leads in CS or other devices impeding device placement

          -  Severe aortic valvular disease

          -  Chronic corticosteroid use other than &lt; 20mg prednisone for arthritis

          -  Significant co-morbidities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luc Bilodeau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital, McGill University Medical Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laval Hospital, Quebec Heart-Lung Institute</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://viacorinc.com</url>
    <description>Sponsor Web Page (multi-lingual)</description>
  </link>
  <reference>
    <citation>Dubreuil O, Basmadjian A, Ducharme A, Thibault B, Crepeau J, Lam JY, Bilodeau L. Percutaneous mitral valve annuloplasty for ischemic mitral regurgitation: first in man experience with a temporary implant. Catheter Cardiovasc Interv. 2007 Jun 1;69(7):1053-61.</citation>
    <PMID>17525965</PMID>
  </reference>
  <reference>
    <citation>Fukuda S, Gillinov AM, Liddicoat JR, Saracino G, Hayase M, Cohn WE, Schneider CW, Shiota T. Maintenance of geometric alterations associated with percutaneous mitral valve repair: real-time three-dimensional echocardiographic assessment in an ovine model. J Heart Valve Dis. 2008 May;17(3):276-82.</citation>
    <PMID>18592924</PMID>
  </reference>
  <reference>
    <citation>Daimon M, Gillinov AM, Liddicoat JR, Saracino G, Fukuda S, Koyama Y, Hayase M, Cohn WE, Ellis SG, Thomas JD, Shiota T. Dynamic change in mitral annular area and motion during percutaneous mitral annuloplasty for ischemic mitral regurgitation: preliminary animal study with real-time 3-dimensional echocardiography. J Am Soc Echocardiogr. 2007 Apr;20(4):381-8.</citation>
    <PMID>17400117</PMID>
  </reference>
  <reference>
    <citation>Noble S, Bilodeau L. [Percutaneous therapies for aortic and mitral valvular disease]. Rev Med Suisse. 2007 May 30;3(113):1360-1, 1363-4, 1366-7. Review. French.</citation>
    <PMID>17645049</PMID>
  </reference>
  <reference>
    <citation>Daimon M, Shiota T, Gillinov AM, Hayase M, Ruel M, Cohn WE, Blacker SJ, Liddicoat JR. Percutaneous mitral valve repair for chronic ischemic mitral regurgitation: a real-time three-dimensional echocardiographic study in an ovine model. Circulation. 2005 May 3;111(17):2183-9. Epub 2005 Apr 25.</citation>
    <PMID>15851597</PMID>
  </reference>
  <reference>
    <citation>Liddicoat JR, Mac Neill BD, Gillinov AM, Cohn WE, Chin CH, Prado AD, Pandian NG, Oesterle SN. Percutaneous mitral valve repair: a feasibility study in an ovine model of acute ischemic mitral regurgitation. Catheter Cardiovasc Interv. 2003 Nov;60(3):410-6.</citation>
    <PMID>14571496</PMID>
  </reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2008</study_first_submitted>
  <study_first_submitted_qc>December 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2008</study_first_posted>
  <last_update_submitted>February 10, 2011</last_update_submitted>
  <last_update_submitted_qc>February 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Katharine M Stohlman, VP Regulatory Affairs</name_title>
    <organization>Viacor, Inc.</organization>
  </responsible_party>
  <keyword>mitral valve</keyword>
  <keyword>heart failure</keyword>
  <keyword>mitral regurgitation</keyword>
  <keyword>annuloplasty</keyword>
  <keyword>coronary sinus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

